OCULOGICA

OCULOGICA offers a revolutionary innovation in the healthcare industry with its EyeBOX technology, aiming to provide more accurate and objective concussion assessments. Founded in 2013 and headquartered in the United States, the company has gained recognition for its groundbreaking approach, as evidenced by its inclusion in the 2020 Fast Company Most Creative Companies list. The EyeBOX sets itself apart with its ability to collect and analyze over 100,000 data points across 67 domains of eye movement within under 4 minutes. This comprehensive analysis enables the generation of unique, objective assessments for each patient, without requiring baseline data or individual calibration, thereby mitigating the potential influence of patient will on the results. One of the key strengths of the EyeBOX lies in its baseline-free nature, which eliminates the need for pre-incident patient data. Moreover, its 67-point analysis provides a level of diagnostic precision that surpasses current standards of care, offering a more comprehensive assessment of brain function beyond just symptoms. The technology's simplicity and calibration-free testing make it accessible across various patient demographics, including pre-verbal and verbally impaired individuals. The company recently secured a significant $7.57M Venture Round investment on 13 May 2024, signifying the confidence of investors in OCULOGICA's innovative approach to concussion assessment. With its pioneering technology and strong financial backing, OCULOGICA is poised to make a significant impact in the healthcare industry by improving patient outcomes and setting new standards for concussion diagnosis and treatment.